Privately Held Biotech Company Reveals This Revolutionary Treatment

Baudax Bio's Acquisition of TeraImmune Sets the Stage for Revolutionary Hemophilia A Treatment

Baudax Bio's Acquisition of TeraImmune Sets the Stage for Revolutionary Hemophilia A Treatment

Introduction

In a groundbreaking move, pharmaceutical company Baudax Bio (NASDAQ: BXRX) has acquired TeraImmune, a privately held biotech company focused on the discovery and development of Treg-based cell therapies. This strategic merger brings TeraImmune's inv…